Myeloid cells are pivotal within the immunosuppressive tumour microenvironment. The
accumulation of tumour-modified myeloid cells derived from monocytes or neutrophils …

Anticancer nanomedicines have been proven effective in mitigating the side effects of
chemotherapeutic drugs. However, challenges remain in augmenting their therapeutic …

Cancer immunotherapy has significantly flourished and revolutionized the limited
conventional tumor therapies, on account of its good safety and long-term memory ability …

Pancreatic ductal adenocarcinoma (PDA) is characterized by an immune-suppressive tumor
microenvironment that renders it largely refractory to immunotherapy. We implemented a …

Multiple nanotherapeutics have been approved for patients with cancer, but their effects on
survival have been modest and, in some examples, less than those of other approved …

Despite significant advances in the field of cancer immunotherapy, the majority of patients
still do not benefit from treatment and must rely on traditional therapies. Dendritic cells have …

Nasopharyngeal carcinoma (NPC) is an aggressive malignancy with extremely skewed
ethnic and geographic distributions. Increasing evidence indicates that targeting the tumor …

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of cells
generated during a large array of pathologic conditions ranging from cancer to obesity …

Circulating tumor cells (CTCs) are the seeds of distant metastasis, and the number of CTCs
detected in the blood of cancer patients is associated with a worse prognosis. CTCs face …

Dendritic cells (DCs) play a central role in the regulation of the balance between CD8 T cell
immunity vs. tolerance to tumor antigens. Cross-priming, a process which DCs activate CD8 …